Mode
Text Size
Log in / Sign up

Serratus anterior plane block reduces postoperative nausea and opioid consumption after surgery under general anesthesiaSerratus Anterior Block May Reduce Nausea After Surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider SAPB to reduce opioid consumption and nausea, though its direct antiemetic effect is not established.

This meta-analysis evaluated the impact of serratus anterior plane block (SAPB) on postoperative nausea and vomiting (PONV) and opioid consumption in 1,651 adults undergoing surgery under general anesthesia. The study synthesized data regarding primary outcomes like PONV incidence and secondary outcomes including pain scores, hospitalization time, and specific opioid requirements.

Key findings indicate that SAPB significantly reduced the incidence of postoperative nausea (RD = -0.17; 95% CI: -0.23 to -0.11). The reduction in vomiting was noted as a borderline finding (RD = -0.13; 95% CI: -0.25 to -0.00). Furthermore, SAPB was associated with significantly lower consumption of fentanyl (SMD = -1.08) and remifentanil (SMD = -2.14), while no significant reduction in sufentanil consumption was reported. Other improvements included lower pain scores, shorter hospital stays, and a reduced incidence of headache.

The authors noted limitations including insufficient reporting of allocation concealment and blinding procedures. While SAPB appears to reduce opioid requirements and improve analgesia in breast and thoracic surgery patients, the evidence does not establish an independent direct antiemetic effect; the reduction in PONV may be secondary to decreased peri-operative opioid requirements.

How this fits prior evidence

This meta-analysis extends prior evidence regarding regional anesthesia as an opioid-sparing adjunct. While previous findings showed peripheral nerve blocks reduced morphine use by 16.20 mg in kidney transplant recipients, this study specifically addresses the role of serratus anterior plane block (SAPB) in reducing postoperative nausea and opioid requirements for patients undergoing surgery under general anesthesia.

Researchers looked at how a specific nerve block, called a serratus anterior plane block (SAPB), affects patients who undergo surgery under general anesthesia. This study analyzed data from 1,651 adults to see if this technique could reduce common side effects like nausea and vomiting, while also managing pain.

The results showed that patients receiving the SAPB had fewer instances of nausea and lower scores for pain. The study also found that these patients required less fentanyl and remifentanil after their surgery. While there was a slight reduction in vomiting, this finding was considered borderline and should be viewed with caution.

It is important to note that it is not yet clear if the nerve block directly stops nausea or if the improvement happens because patients need fewer opioids. Because of this, the results are currently seen as moderate certainty. Patients should talk to their surgical team to see if this specific technique is appropriate for their recovery plan.

What this means for you:
The serratus anterior plane block may reduce post-surgery nausea and lower the amount of opioid medication needed.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Postoperative nausea and vomiting (PONV) still often occurs after surgery, which adversely affects recovery and patient satisfaction. Serratus anterior plane block (SAPB) has been proposed as a regional anesthesia technique that may reduce PONV indirectly by improving postoperative analgesia and decreasing perioperative opioid requirements. A systematic review and meta-analysis of the randomized controlled trial (RCT) was conducted to evaluate the impact of SAPB on PONV. From its establishment to April 20, 2026, the central register of PubMed, Embase, CNKI and Cochrane controlled trials was searched. Eligible studies include adults who underwent surgery under general anesthesia with a control group (placebo or no intervention). The main results are the incidence of postoperative nausea and vomiting; the secondary results include postoperative opioid consumption, pain score (visual analog scale, VAS), hospitalization time, the time of first rescue analgesia, and the incidence of headache or hypotension. Random effect element analysis was carried out to gather risk differences (RD) and standardized mean differences (SMD) with 95% confidence intervals (CI). Use GRADE to evaluate the certainty of evidence and apply test sequence analysis (TSA) to evaluate robustness. Twenty RCTs involving 1,651 patients were included. Compared with control treatment, SAPB was associated with a reduced incidence of postoperative nausea (RD = −0.17; 95% CI: −0.23 to −0.11; I2 = 67%; moderate-certainty evidence). SAPB may also reduce postoperative vomiting, although this finding was borderline and should be interpreted cautiously (RD = −0.13; 95% CI: −0.25 to −0.00; I2 = 79%; moderate-certainty evidence). SAPB reduced fentanyl consumption (SMD = −1.08; 95% CI: −1.86 to −0.31) and remifentanil consumption (SMD = −2.14; 95% CI: −3.25 to −1.03), whereas sufentanil consumption was not significantly reduced. SAPB also improved postoperative pain scores, shortened hospital stay, prolonged the time to first rescue analgesia, and reduced headache incidence. Funnel plot inspection and Egger’s and Begg’s tests did not suggest significant small-study effects for postoperative nausea. Risk-of-bias concerns were mainly related to insufficient reporting of allocation concealment and blinding procedures. SAPB appears to reduce postoperative opioid requirements and improve analgesia in patients undergoing breast and thoracic surgery. These benefits are associated with a reduced incidence of postoperative nausea and may contribute to enhanced recovery. However, the current evidence does not establish an independent direct antiemetic effect of SAPB, and the effect on postoperative vomiting should be interpreted cautiously. Further high-quality RCTs with standardized opioid and antiemetic protocols are needed to clarify the causal pathway between SAPB, opioid reduction, and PONV. https://www.crd.york.ac.uk/prospero/CRD420261373467, identifier CRD420261373467.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.